Immuneering

IMRX · NASDAQ

$3.73+$0.27 (+7.80%)TodayMarket closed ·
Prev close $3.46

Latest news

  • Press releaseGlobe Newswire

    Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

  • Press releaseGlobe Newswire

    Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

  • Press releaseGlobe Newswire

    Immuneering to Present at the ESMO Congress 2026

  • Press releaseGlobe Newswire

    Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

  • Press releaseGlobe Newswire

    Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

  • Press releaseGlobe Newswire

    Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

  • Press releaseGlobe Newswire

    Immuneering Corporation Announces Grants of Inducement Awards

  • Press releaseGlobe Newswire

    Immuneering Appoints Andrew Gengos as Chief Financial Officer

  • Press releaseGlobe Newswire

    Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

  • NewsAvi Kapoor

    Crude Oil Edges Higher; US Consumer Sentiment Falls In May

  • News

    Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet

  • NewsAvi Kapoor

    Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • NewsAvi Kapoor

    Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings

  • NewsRishabh Mishra

    Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED)

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday

  • NewsAvi Kapoor

    Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday

  • Press releasePRNewswire

    Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

  • Press releaseGlobe Newswire

    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

  • Press releaseGlobe Newswire

    Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

  • News

    Earnings Scheduled For November 12, 2025

  • News

    A Preview Of Immuneering's Earnings

  • Press releasePRNewswire

    Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

  • Press releasePRNewswire

    With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releasePRNewswire

    How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

  • NewsChris Katje

    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

  • NewsAvi Kapoor

    Nasdaq Surges 1%; Meta Posts Upbeat Earnings

  • NewsAvi Kapoor

    Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

  • News

    Market-Moving News for August 1st

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.